Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2020 | Initial results of the phase III BOSTON study

Meletios Dimopoulos • 22 May 2020
ASCO 2020
Multiple Myeloma Bortezomib Dexamethasone Selinexor
BOSTON

Meletios Dimopoulos, MD, University of Athens School of Medicine, Athens, Greece, gives an update on data from the BOSTON study (NCT03110562) – the first phase III study to evaluate the clinical benefit of selinexor with bortezomib and dexamethasone (SVd) for relapsed/refractory multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Meletios Dimopoulos

MagnetisMM-6 trial cohort G data: assessing EDR in transplant-ineligible newly diagnosed myeloma 2:08
MagnetisMM-6 trial cohort G data: assessing EDR in transplant-ineligible newly diagnosed myeloma
Meletios Dimopoulos • 12 Jun 2025
Updated results from DREAMM-8: belamaf plus pomalidomide and dexamethasone in R/R myeloma 2:00
Updated results from DREAMM-8: belamaf plus pomalidomide and dexamethasone in R/R myeloma
Meletios Dimopoulos • 12 Jun 2025
The use of MRD to guide maintenance therapy discontinuation in patients with multiple myeloma 1:58
The use of MRD to guide maintenance therapy discontinuation in patients with multiple myeloma
Meletios Dimopoulos • 6 Dec 2024
HRQoL in patients with transplant-ineligible NDMM treated with Isa-VRd in the IMROZ study 0:52
HRQoL in patients with transplant-ineligible NDMM treated with Isa-VRd in the IMROZ study
Meletios Dimopoulos • 6 Dec 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals